Lck pY505 Antibody, anti-human, REAfinity™
Synonyms: LSK
RECOMBINANT EXTENDED VALIDATION
Bioz Star90/100 Bioz rating
2 Citations
Clone:
REA673 | 4/Lck-Y505
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for Lck pY505 Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
Vio B515
Description:
Jurkat cells were either left unstimulated (left peak) or stimulated with 5 mM H2O2 for 15 minutes. Cells were then fixed and permeabilized using the Cell Signaling Buffer Set A followed by intracellular staining with Anti-Lck pY505 antibodies. Flow cytometry was performed using the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.
Intracellular flow cytometry applications
APC
PE
Vio B515
Recommended dilution:
1:11
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-110-285, 130-110-386
Description:
Jurkat cells were either left unstimulated (left peak) or stimulated with 5 mM H2O2 for 15 minutes. Cells were then fixed and permeabilized using the Cell Signaling Buffer Set A followed by intracellular staining with Anti-Lck pY505 antibodies. Flow cytometry was performed using the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application image
Extended validation for Lck pY505 Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA673
4/Lck-Y505
partial
SRRCHA
partial

Cells were incubated with an excess of purified unconjugated Lck pY505 (REA673) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Specifications for Lck pY505 Antibody, anti-human, REAfinity™
Overview

Clone REA673 recognizes the human Lck antigen, phosphorylated at tyrosine 505. Lck is a non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T cells in the thymus and in the function of mature T cells. It is expressed at all stages of thymocyte development and is required for the regulation of maturation events that are governed by both pre-TCR and mature α/β TCR. Lck plays a key role in the T cell antigen receptor (TCR)–linked signal transduction pathways and is constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors. Association of the TCR with a peptide antigen-bound MHC complex facilitates the interaction of CD4 and CD8 with MHC class II and class I molecules, respectively, thereby recruiting the associated Lck protein to the vicinity of the TCR/CD3 complex. Lck then phosphorylates tyrosines residues within the immunoreceptor tyrosine-based activation motifs of the cytoplasmic tails of the TCR-γ chains and CD3 subunits, initiating the TCR/CD3 signaling pathway. Lck also contributes to signaling by other receptor molecules. It associates directly with the cytoplasmic tail of CD2, which leads to hyperphosphorylation and activation of Lck, and also plays a role in the IL-2 receptor-linked signaling pathway that controls the T cell proliferative response. Binding of IL-2 to its receptor results in increased activity of Lck. Phosphorylated Tyr-505 associates with the SH2 domain in the amino-terminal half of the protein.

Additional information: Clone REA673 displays negligible binding to Fc receptors.

Alternative names

LSK

Detailed product information

Technical specifications

Clone
REA673
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human, mouse, other
Cross-reactivity
mouse, chicken
Antigen
Lck pY505
Molecular mass of antigen [kDa]
58
Distribution of antigen
T cells, thymocytes
Entrez Gene ID
RRID
AB_2652606, AB_2652605, AB_2652607, AB_2652604, AB_2928743, AB_2928744

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for Lck pY505 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?